

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)

As At 30 June 2012

	30-06-2012 Taka	31-03-2012 Taka
ASSETS:		
Non-Current Assets:	17,227,978,062	16,128,144,622
Property, Plant and Equipment-Carrying Value	9,670,288,198	9,171,791,457
Capital Work-in-Progress	1,737,823,825	1,274,390,572
Investment - Long Term (at Cost)	167,694,430	167,694,430
Investment - Associates Undertaking	4,809,785,416	4,709,080,125
Investment in Marketable Securities (Fair Value)	840,979,705	804,638,100
Preoperating/Preliminary Expenses	1,406,488	549,938
Current Assets:	7,699,188,839	8,248,571,022
Inventories	3,634,376,493	3,178,672,614
Trade Debtors	842,153,455	819,002,633
Advances, Deposits and Prepayments	994,809,677	694,844,720
Short Term Loan	1,492,439,662	1,717,273,322
Margin against BTB Letter of Credit	-	1,091,148,736
Cash and Cash Equivalents	735,409,552	747,628,997
TOTAL ASSETS	24,927,166,901	24,376,715,644
SHAREHOLDERS' EQUITY AND LIABILITIES:		
Shareholders' Equity:	20,133,051,651	19,120,019,851
Share Capital	2,648,347,600	2,648,347,600
Share Premium	2,035,465,000	2,035,465,000
General Reserve	105,878,200	105,878,200
Tax Holiday Reserve	449,870,449	449,870,449
Gain on Marketable Securities (Unrealized)	450,487,120	420,437,468
Retained Earnings	14,443,003,282	13,460,021,134
Non Controlling Interest	7,543,392	7,339,774
Non-Current Liabilities:	902,570,422	933,965,662
Long Term Loans - Secured	477,382,820	508,778,060
Deffered Tax Liability	425,187,602	425,187,602
Current Liabilities:	3,884,001,436	4,315,390,357
Short Term Bank Loans	2,320,231,151	2,237,495,956
Long Term Loans-Current Portion	451,199,581	477,141,480
Trade Creditors	42,012,597	531,295,427
Liabilities for Expenses	54,567,921	114,515,510
Liabilities for Other Finance	1,015,990,186	954,941,984
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	24,927,166,901	24,376,715,644

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) For the 1st Quarter Ended 30 June 2012

	April-June 2012 Taka	April-June 2011 Taka
GROSS TURNOVER	4,928,699,619	5,206,232,203
Less: Value Added Tax	670,476,572	668,281,988
NET TURNOVER	4,258,223,047	4,537,950,215
Cost of Goods Sold	(2,233,263,504)	(2,524,871,310)
GROSS PROFIT	2,024,959,543	2,013,078,905
Operating Expenses:	(938,762,518)	(914,973,731)
Selling & Distribution Expenses	(675,000,645)	(625,751,919)
Administrative Expenses	(176,045,210)	(172,688,979)
Financial Expenses	(87,716,663)	(116,532,833)
PROFIT FROM OPERATIONS	1,086,197,025	1,098,105,174
Other Income	67,959,836	104,846,098
PROFIT BEFORE WPPF	1,154,156,861	1,202,951,272
Allocation for WPPF	(58,360,858)	(57,283,394)
PROFIT BEFORE TAX	1,095,796,003	1,145,667,878
Provision for Income Tax	(284,744,035)	(286,533,069)
PROFIT AFTER TAX	811,051,968	859,134,809
Profit/(Loss) from Associates Undertaking	172,133,798	115,957,335
PROFIT FOR THE YEAR	983,185,766	975,092,144
Other Comprehensive Income:		
Gain on Marketable Securities (Unrealized)	30,049,652	(11,699,637)
Total Comprehensive Income for the Year	1,013,235,418	963,392,507
Profit Attributable to:		
Owners of the Company	982,982,148	974,799,874
Non Controlling Interest	203,618	292,270
	983,185,766	975,092,144
Total Comprehensive Income Attributable to:		
Owners of the Company	1,013,031,800	963,100,237
Non Controlling Interest	203,618	292,270
	1,013,235,418	963,392,507
Earnings Per Share (EPS)	3.71	3.68
Number of Shares used to compute EPS	264,834,760	264,834,760

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the 1st Quarter Ended 30 June 2012

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Non Controlling Interest Taka	Total Taka
At 31 March 2012	2,648,347,600	2,035,465,000	105,878,200	449,870,449	420,437,468	13,460,021,134	7,339,774	19,127,359,625
Total Comprehensive Income (Apr'12-Jun'12)	-	-	-	-	30,049,652	982,982,148	203,618	1,013,235,418
At 30 June 2012	2,648,347,600	2,035,465,000	105,878,200	449,870,449	450,487,120	14,443,003,282	7,543,392	20,140,595,043

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the 1st Quarter Ended 30 June 2011

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Non Controlling Interest Taka	Total Taka
At 31 March 2011	1,961,739,000	2,035,465,000	105,878,200	1,532,954,925	294,179,676	10,033,495,983	5,849,133	15,969,561,917
Total Comprehensive Income (Apr'11-Jun'11)	-	-	-	-	(11,699,637)	974,799,874	292,270	963,392,507
Transfer to Tax Holiday Reserve	-	-	-	2,804,167	-	(2,804,167)	-	-
At 30 June 2012	1,961,739,000	2,035,465,000	105,878,200	1,535,759,092	282,480,039	11,005,491,690	6,141,403	16,932,954,424

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

For the 1st Quarter Ended 30 June 2012

	1st Quarter Ended 30th June 2012 Taka	1st Quarter Ended 30th June 2011 Taka
Cash Flows From Operating Activities:		
RECEIPTS:		
Collection from Sales	4,884,151,555	5,782,473,427
Others	19,819,292	43,532,082
	4,903,970,847	5,826,005,509
PAYMENTS:		
Purchase of Raw and Packing Materials	1,440,078,974	2,478,160,142
Manufacturing and Operating Expenses	1,547,211,546	1,422,361,102
Value Added Tax	670,476,572	668,281,988
Bank Interest	87,716,663	116,532,833
Income Tax	282,821,330	242,184,086
Workers Profit Participation Fund	15,482,445	23,657,883
	4,043,787,530	4,951,178,034
Net cash provided by operating activities	860,183,317	874,827,475
Cash Flows From Investing Activities:		
Purchase of Fixed Assets	(771,723,919)	(506,248,994)
Pre-operating Cost	(856,550)	-
Investment in Marketable Securities	(6,291,953)	(40,476,412)
Short Term Loan	224,833,660	36,388,892
Capital Work-in-Progress	(463,433,253)	(251,530,989)
Interest Received	47,793,050	46,302,940
Dividend Received	71,878,147	17,854,255
	(897,800,818)	(697,710,308)
Net cash used in investing activities		
Cash Flows From Financing Activities:		
Long Term Loan Received	600,000	275,013,371
Long Term Loan Repaid	(57,937,139)	(75,194,538)
Short Term Bank Loan Increase/(Decrease)	82,735,195	(337,997,452)
	25,398,056	(138,178,619)
Net cash provided/(used) by financing activities		
Increase in Cash and Cash Equivalents	(12,219,445)	38,938,548
Cash and Cash Equivalents at the Opening	747,628,997	429,307,393
Cash and Cash Equivalents at the Closing	735,409,552	468,245,941

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

1ST QUARTER FINANCIAL STATEMENTS STATEMENT OF FINANCIAL POSITION (Unaudited) As At 30 June 2012

	30-06-2012 Taka	31-03-2012 Taka
ASSETS:		
Non-Current Assets:	15,768,032,244	14,707,876,362
Property, Plant and Equipment-Carrying Value	9,310,056,350	8,767,827,062
Capital Work-in-Progress	1,737,823,825	1,274,390,572
Investment - Long Term (at Cost)	3,990,334,172	3,970,621,331
Investment in Marketable Securities (Fair Value)	729,817,897	695,037,397
Current Assets:	6,828,495,648	6,745,908,400
Inventories	3,163,698,218	2,687,818,472
Trade Debtors	826,505,269	808,311,714
Advances, Deposits and Prepayments	683,181,170	577,156,445
Short Term Loan	1,492,439,662	2,085,701,502
Cash and Cash Equivalents	662,671,329	586,920,267
TOTAL ASSETS	22,596,527,892	21,453,784,762
SHAREHOLDERS' EQUITY AND LIABILITIES:		
Shareholders' Equity:	17,143,959,671	16,266,884,255
Share Capital	2,648,347,600	2,648,347,600
Share Premium	2,035,465,000	2,035,465,000
General Reserve	105,878,200	105,878,200
Gain on Marketable Securities (Unrealized)	432,907,723	399,421,439
Retained Earnings	11,921,361,148	11,077,772,016
Non-Current Liabilities:	902,570,422	933,965,662
Long Term Loans - Secured	477,382,820	508,778,060
Deffered Tax Liability	425,187,602	425,187,602
Current Liabilities:	4,549,997,799	4,252,934,845
Short Term Bank Loans	2,083,303,478	2,016,551,125
Long Term Loans - Current Portion	451,199,581	477,141,480
Trade Creditors	1,108,554,734	875,431,555
Liabilities for Expenses	54,567,921	95,361,435
Liabilities for Other Finance	852,372,085	788,449,250
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	22,596,527,892	21,453,784,762

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

STATEMENT OF COMPREHENSIVE INCOME (Unaudited) For the 1st Quarter Ended 30 June 2012

	April-June 2012 Taka	April-June 2011 Taka
GROSS TURNOVER	4,446,687,386	4,362,995,969
Less: Value Added Tax	601,668,931	597,758,147
NET TURNOVER	3,845,018,455	3,765,237,822
Cost of Goods Sold	(2,005,395,874)	(1,970,596,537)
GROSS PROFIT	1,839,622,581	1,794,641,285
Operating Expenses:	(892,927,780)	(864,913,770)
Selling & Distribution Expenses	(642,550,629)	(596,861,565)
Administrative Expenses	(174,370,383)	(165,415,506)
Financial Expenses	(76,006,768)	(102,636,699)
PROFIT FROM OPERATIONS	946,694,801	929,727,515
Other Income	213,558,110	183,326,846
PROFIT BEFORE WPPF	1,160,252,911	1,113,054,361
Allocation for WPPF	(55,250,139)	(53,002,589)
PROFIT BEFORE TAX	1,105,002,772	1,060,051,772
Provision for Income Tax	(261,413,640)	(257,055,936)
PROFIT AFTER TAX FOR THE PERIOD	843,589,132	802,995,836
Other Comprehensive Income :		
Gain/(Loss) on Marketable Securities (Unrealized)	33,486,284	(7,705,491)
Total Comprehensive Income for the Year	877,075,416	795,290,345
Earnings Per Share (EPS)	3.19	3.03
Number of Shares used to compute EPS	264,834,760	264,834,760

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the 1st Quarter Ended 30 June 2012

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Total Taka
At 31 March 2012	2,648,347,600	2,035,465,000	105,878,200	-	399,421,439	11,077,772,016	16,266,884,255
Total Comprehensive Income (Apr'2012-Jun'2012)	-	-	-	-	33,486,284	843,589,132	877,075,416
At 30 June 2012	2,648,347,600	2,035,465,000	105,878,200	-	432,907,723	11,921,361,148	17,143,959,671

SQUARE PHARMACEUTICALS LTD.STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the 1st Quarter Ended 30 June 2011

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Total Taka
At 31 March 2011	1,961,739,000	2,035,465,000	105,878,200	1,101,935,237	259,435,115	8,353,256,438	13,817,708,990
Total Comprehensive Income (Apr'2011-Jun'2011)	-	-	-	-	(7,705,491)	802,995,836	795,290,345
At 30 June 2011	1,961,739,000	2,035,465,000	105,878,200	1,101,935,237	251,729,624	9,156,252,274	14,612,999,335

Sd/-
Tapan Chowdhury
Managing DirectorSd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LTD.

STATEMENT OF CASH FLOWS (Unaudited) For the 1st Quarter Ended 30 June 2012

	1st Quarter Ended 30th June 2012 Taka	1st Quarter Ended 30th June 2011 Taka
Cash Flows From Operating Activities:		
RECEIPTS:		
Collection from Sales	4,425,880,220	4,444,883,085
Others	94,069,459	119,612,914
	4,519,949,679	4,564,495,999
PAYMENTS:		
Purchase of Raw and Packing Materials	1,676,928,772	1,663,212,206
Manufacturing and Operating Expenses	1,288,452,594	1,292,355,988
Value Added Tax	601,668,931	597,758,147
Bank Interest	76,006,768	102,636,699
Income Tax	255,204,180	230,772,130
Workers Profit Participation Fund	15,288,495	23,482,383
	3,913,549,740	3,910,217,553
Net cash provided by operating activities	606,399,939	654,278,446
Cash Flows From Investing Activities:		
Purchase of Fixed Assets	(768,376,418)	(476,185,791)
Capital Work-in-Progress	(463,433,253)	(251,530,989)
Interest Received	47,793,050	48,616,286
Dividend Received	71,697,747	17,854,255
Short Term Loan	593,261,840	127,511,077
Investment in Marketable Securities	(1,294,216)	-
Long Term Investment	(19,712,841)	(15,000,000)
	(540,064,091)	(548,735,162)
Net cash used in investing activities	(540,064,091)	(548,735,162)
Cash Flows From Financing Activities:		
Long Term Loan Received	600,000	275,013,371
Long Term Loan Repaid	(57,937,139)	(65,194,538)
Short Term Bank Loan Increase/(Decrease)	66,752,353	(291,581,171)
	9,415,214	(81,762,338)
Net cash (used)/provided in financing activities	9,415,214	(81,762,338)
Increase in Cash and Cash Equivalents	75,751,062	23,780,946
Cash and Cash Equivalents at the Opening	586,920,267	370,301,755
Cash and Cash Equivalents at the Closing	662,671,329	394,082,701

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer